285.42  2.02 (0.71%)		10-16 16:00
Open: 283.47 High: 286.63 Volume: 5,638,833		Pre. Close: 283.4 Low: 283.01 Market Cap: 504,371(M)

Short term
Mid term
Targets	6-month :	340.35	1-year :	397.53
Resists	First :	291.39	Second :	340.35
Pivot price	271.61
Supports	First :	270.63	Second :	257.79
MAs	MA(5) :	281.53	MA(20) :	269.92
	MA(100) :	250.94	MA(250) :	230.04
MACD	MACD :	6	Signal :	4.3
%K %D	K(14,3) :	83.8	D(3) :	82.3
RSI	RSI(14): 71
52-week	High :	291.39	Low :	189.4

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ABBV ] has closed below upper band by 9.0%. Bollinger Bands are 41.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	286.9 - 288.29	288.29 - 289.49
Low:	279.65 - 281.27	281.27 - 282.67
Close:	283 - 285.5	285.5 - 287.67

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Fri, 16 Oct 2026
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance

Fri, 16 Oct 2026
AbbVie vs. Merck: Which Pharma Stock Offers Better Value? - Yahoo Finance

Fri, 16 Oct 2026
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? - Yahoo Finance

Fri, 16 Oct 2026
5 Stock Ideas for Your Short List - TradingView

Thu, 15 Oct 2026
AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands - Yahoo Finance

Wed, 14 Oct 2026
AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis - TradingKey

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	1,770 (M)
Shares Float	1,760 (M)
Held by Insiders	0.1 (%)
Held by Institutions	77.3 (%)
Shares Short	16,280 (K)
Shares Short P.Month	19,510 (K)

EPS	3.53
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-3.36
Profit Margin	9.8 %
Operating Margin	40 %
Return on Assets (ttm)	10.5 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	10.1 %
Gross Profit (p.s.)	26.48
Sales Per Share	36.37
EBITDA (p.s.)	17.37
Qtrly Earnings Growth	290.3 %
Operating Cash Flow	19,510 (M)
Levered Free Cash Flow	16,870 (M)

PE Ratio	80.62
PEG Ratio	0.5
Price to Book value	-84.95
Price to Sales	7.84
Price to Cash Flow	25.89

Dividend	1.73
Forward Dividend	0
Dividend Yield	0.6%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.